Core 2: Neuro-Imaging Core

核心 2：神经影像核心

基本信息

批准号：
9983045
负责人：
Benjamin M. Ellingson
金额：
$ 15.63万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-11 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9983045
关键词：
Address Amines Anatomy Angiogenesis Inhibitors Antineoplastic Agents Archives Biological Markers Blood Vessels Brain Neoplasms Cells Cellularity Clinic Clinical Clinical Trials Clofarabine Companions Complex Computer software Cytosine Data Diagnostic radiologic examination Diffusion Diffusion Magnetic Resonance Imaging Environment Epidermal Growth Factor Receptor Erlotinib Evaluation Functional Imaging Glioblastoma Glioma Goals Human Image Analysis Imaging Techniques Immune response Immunotherapy In Situ Individual International Link Magnetic Resonance Imaging Malignant neoplasm of brain Measurement Metabolic Outcome Patient imaging Patients Perfusion Physiological Positron-Emission Tomography Procedures Process Protocols documentation Public Health Recurrent tumor Research Personnel Resources Secure Sorting - Cell Movement Standardization Techniques Testing Therapeutic Therapeutic Clinical Trial Tracer Translations Tumor Biology Vaccines Vascular Permeabilities brain tumor imaging cerebral blood volume clinical imaging effective therapy experience fluorodeoxyglucose fluorodeoxyglucose positron emission tomography imaging approach in vivo insight metabolic imaging molecular imaging mutant neuro-oncology neuroimaging non-invasive imaging novel novel therapeutic intervention novel therapeutics outcome forecast perfusion imaging pre-clinical preclinical imaging response spatiotemporal spectroscopic imaging tool treatment response tumor tumor metabolism uptake

项目摘要

Core 2: Neuro-Imaging Core (NIC) SUMMARY/ABSTRACT The extremely poor prognosis and lack of effective treatments for glioblastoma (GBM) remains a significant public health issue. While traditional MRI techniques are valuable in determining GBM response to common anti-neoplastic therapies, novel treatments including immunotherapies, anti-angiogenic agents, or therapies that alter tumor metabolism may result in radiographic changes that are challenging to differentiate from non- responsive or growing tumor. Therefore, the primary goal of the Neuro-Imaging Core (NIC) will be to provide advanced MRI and PET imaging support with established reliability and consistency to SPORE project investigators for their respective projects. Specifically, the NIC will use quantitative MRI and PET for pre- clinical imaging (Aim 1) and state-of-the-art MR and PET imaging acquisition, advanced post-processing, and novel analysis tools for clinical imaging of patients in novel clinical trials (Aim 2). Hence, this Core will add value to the overall SPORE by helping investigators to better understand the in situ metabolic, physiologic, and traditional radiographic changes within the brain and tumor in order to address specific objectives of each of the UCLA Brain Cancer SPORE projects. Another main goal of the NIC is to understand the link between metabolic and/or physiologic imaging and tumor biology in order to reliably delineate treatment response versus recurrent tumor (Aim 3), which in turn will facilitate the direct translation of new MR-PET companion biomarkers/techniques to the clinic for the evaluation of treatment response in ongoing and new therapeutic clinical trials resulting from the SPORE projects and cores.

核心 2：神经影像核心 (NIC) 摘要/摘要胶质母细胞瘤（GBM）极差的预后和缺乏有效的治疗方法仍然是一个重要的问题虽然传统的 MRI 技术对于确定 GBM 对常见问题的反应很有价值。抗肿瘤疗法、新疗法，包括免疫疗法、抗血管生成剂或疗法改变肿瘤代谢可能会导致放射学变化，这些变化很难与非肿瘤区分开来。因此，神经影像核心 (NIC) 的主要目标是提供反应性或生长中的肿瘤。先进的 MRI 和 PET 成像支持，与 SPORE 项目具有既定的可靠性和一致性具体来说，NIC 将使用定量 MRI 和 PET 进行预检测。临床成像（目标 1）以及最先进的 MR 和 PET 成像采集、先进的后处理以及用于新临床试验中患者临床成像的新分析工具（目标 2）因此，该核心将添加。通过帮助研究人员更好地了解原位代谢、生理和大脑和肿瘤内的传统射线照相变化，以解决每个的特定目标加州大学洛杉矶分校脑癌 SPORE 项目的另一个主要目标是了解之间的联系。代谢和/或生理成像和肿瘤生物学，以便可靠地描述治疗反应与复发性肿瘤（目标 3）相比，这反过来将促进新 MR-PET 伴侣的直接转化临床用于评估正在进行的和新的治疗方法的治疗反应的生物标志物/技术 SPORE 项目和核心产生的临床试验。